C

인벤티지랩

389470KOSDAQ

44.9 / 100

Reference Date: 2026-09-08

Financial Score15.0 / 40
News Sentiment16.9 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

InventiZ Lab is a DDS (Drug Delivery System) platform company leveraging microfluidics-based Laminar-FLUIDigm™ technology to develop long-acting injectables and gene delivery solutions. It utilizes the IVL-DrugFluidic® platform for improved new drug development and the IVL-GeneFluidic® platform for LNP formulation services for mRNA vaccines, alongside expanding CDMO (Contract Development and Manufacturing Organization) operations. The company currently produces and sells Durahart SR-3 injectable solution and is advancing multiple drug candidates, including IVL3001, IVL3003, and IVL3004, through various clinical trials.

Number of Employees

73people

Average Salary

44.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 15.004.0Point
PBR
4.31Industry Average 1.200.0Point

3.6x industry avg (risky)

ROE
-28.06Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
12.37Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲117.9% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼34.2% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -91.6% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 2Neutral 2Negative 0Average Sentiment Score 67.5

Detailed Momentum

52-week position1.0Point

Near 52w low (1%, downtrend)

Current 26,200Won52-week high 99,50052-week low 24,750
1-month return0.0Point

1m -16.43% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral반기보고서 (2026.06)2026-08-26